• Register to Access the Free Forums and 3 Free CEUs!

    To view the content for the 3 free CEUs, please sign up today.

    CLICK HERE TO REGISTER
  • Missing Access To A Course, Blitz or Exam? Have Technical Issues? Open a Help Desk Ticket
    Please Do Not Post in the Community About Access or Technical Issues
    CCO Business Hours for Help Desk and Coaching: Mon-Fri 9am-4pm Eastern

Resource HCPCS Updates

Code +G2211

If you are Primary Care or other specialty that manages complex conditions over a long term, take note of this new Medicare code for 2021. To be appended to office visit codes. CMS indicated that they expected Primary Care to append this 90-100% of the time.

+G2211 - Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient’s single, serious condition or a complex condition. (Add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established)
 
CMS releases HCPCS codes for COVID-19 antibody drug

The two drugs are administered together and reported using the following new HCPCS codes:

The drugs are not authorized for use in patients who are hospitalized or require oxygen therapy due to COVID-19, or for people currently using chronic oxygen therapy because of an underlying comorbidity.
  • Q0243, injection, casirivimab and imdevimab, 2400 mg
  • M0243, intravenous infusion, casirivimab and imdevimab includes infusion and post-administration monitoring
 
Make sure you’re using the latest code files for your Medicare claims.

 
Related CR Release Date: April 26, 2021
Effective Date: July 1, 2021

Addition of the QW modifier to HCPCS code 87636 [Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique]. CMS included HCPCS code 87636 in Transmittal R10575CP (CR 12080) with an effective date of October 6, 2020.

 

CMS Updates HCPCS Level II for Q2​

Coding highlights and other insight.​

The HCPCS code set used to report medical services and supplies will include 37 new codes effective April 1, 2022.

The resulting new codes are:

H2038 Skills training and development, per diem

T2050 Financial management, self-directed, waiver; per diem

T2051 Supports brokerage, self-directed, waiver; per diem

K1031 Non-pneumatic compression controller without calibrated gradient pressure

K1032 Non-pneumatic sequential compression garment, full leg

K1033 Non-pneumatic sequential compression garment, half leg

Beginning April 1, you will have the following codes to report these supplies:

A2011 Supra sdrm, per square centimeter

A2012 Suprathel, per square centimeter

Beginning April 1, you will use the following code to report InnovaMatrix FX:

A2013 Innovamatrix fs, per square centimeter

 
The effective date of Q0221 is Feb. 24, 2022.

HCPCS Level II code for tixagevimab co-packaged with cilgavimab (EVUSHELD™), which providers administer as a preventive medicine for certain patients before exposure to COVID-19.

Dosage is the only difference between new code Q0221.

 
HCPCS Level II October 2022 update to the code file from the Centers for Medicare & Medicaid Services (CMS) includes more than 40 changes, and most of them are new codes.

5 Wound Care and Graft Supply Codes
A revision to a code for human tissue allografts (grafts where the recipient is not the donor)
Codes for Systems, Devices, and Other Supplies
Codes for Drugs and Other Agents
Codes for Doula and Chaplain Services
Medicaid Standalone Vax Counseling Codes (May 2022)

Read more here:

 

New HCPCS Codes for Reporting Services and Supplies to Medicare​

New modifiers & new codes.

Modifiers:

Modifier AB Audiology service furnished personally by an audiologist without a physician/NPP order for non-acute hearing assessment unrelated to disequilibrium, or hearing aids, or examinations for the purpose of prescribing, fitting, or changing hearing aids; service may be performed once every 12 months, per beneficiary is for use with existing CPT® codes to identify audiology services furnished without the order of a physician or nonphysician practitioner (NPP).

Modifier JZ Zero drug amount discarded/not administered to any patient is to identify no waste was discarded from a single-dose vial drug. CMS has published a FAQ on the Discarded Drugs and Biologicals – JW Modifier and JZ Modifier Policy.

Modifier LU Fractionated payment of CAR-T therapy will hopefully resolve some of the issues providers have been experiencing with CAR-T therapy claims.

3 new modifiers for home oxygen sue under national coverage determination 240.2 to indicate the appropriate treatment regimen and presence of supporting documentation for each Medicare patient group:

  • N1 Group 1 oxygen coverage criteria met
  • N2 Group 2 oxygen coverage criteria met
  • N3 Group 3 oxygen coverage criteria met
New codes:

A4239 Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service

C1747 Endoscope, single-use (i.e. disposable), urinary tract, imaging/illumination device (insertable)

C1826-C1827 for implantable neurostimulator generators

C7500-C7555 for reporting debridement, percutaneous breast biopsies, percutaneous vertebral augmentations, bronchoscopy, catheter placement, and other services

C7900-C7902 for diagnosis of a mental health or substance use disorder

C9143-C9144 to report cocaine nasal solution or injection

E2103 Non-adjunctive, non-implanted continuous glucose monitor or receiver

G0316-G0318 for prolonged services

G0320-G0323 for home health and care management services

G0330 Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room

G3002-G3003 for chronic pain management and treatment

There are many new J codes for injectable drugs and many payment changes for existing J codes such as:

J2327 Injection, risankizumab-rzaa, intravenous, 1 mg

This code was requested by AbbVie to identify SKYRIZI® to report intravenous infusion for the treatment of moderately to severely active Crohn’s disease in adults and distinguish it from the subcutaneous formulation for the treatment of plaque psoriasis and psoriatic arthritis.

J0225 Injection, vutrisiran, 1 mg

This code identifies AMVUTTRA™, which is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

J1954 Injection, leuprolide acetate for depot suspension (lutrate), 7.5 mg

This code is for a drug indicated for use as a palliative treatment of advanced prostate cancer.

M0001-M1210 codes report patient histories

Q4262-Q4264 are skin substitute codes

Q5126 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg

This code is for a biosimilar to Avastin. Alymsys is a vascular endothelial growth factor inhibitor used to treat various types of cancers.

The official January 2023 update of the HCPCS Level II code system is available on CMS.gov.

 
Back
Top